GoodRx Holdings Inc (GDRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$3.48-1.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · GDRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -47.2% |
| Our one-year growth estimate | diamond | 5.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 22 industry peers · Company calendar date is not available
GDRX — earnings in line
Dated 2026-08-05
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: High growth in Pharma Direct revenue helps GoodRx's long-term plans and market position.
Supportive ifPharma Direct revenue growth exceeds 70% year-over-year in the next quarter.
Worry ifPharma Direct revenue growth is below 70% compared to last year.
Why it matters: A drop in active consumers shows problems in the main prescription business. This affects revenue.
Worry ifMonthly Active Consumers decrease by more than 10% compared to the previous quarter.
Less concerning ifMonthly Active Consumers are up or steady compared to last quarter.
Why it matters: Management raised revenue guidance for the year. This shows confidence in their growth plan.
Supportive ifManagement confirms revenue guidance of $765M to $785M for FY 2026 in Q2.
Worry ifManagement lowers revenue guidance below $765M for FY 2026 in Q2.
Why it matters: The earnings report will show how GoodRx is doing in the market.
Watch forEarnings report shows revenue and profit margins are better than expected.
Also watch forEarnings report shows revenue and profit margins are worse than expected.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$244 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $542 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,282 loss on $10,000 · 62.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management aims for Adjusted EBITDA over $235M for FY 2026. Meeting this shows financial health.
Supportive ifManagement says Adjusted EBITDA guidance is more than $235M in Q2.
Worry ifManagement says Adjusted EBITDA guidance is less than $235M in Q2.
Why it matters: A drop below the median would indicate a slowdown in the healthcare sector, affecting GoodRx.
Worry ifHealthcare sector revenue growth reported below its median.
Less concerning ifHealthcare sector revenue growth remains above its median.
Why it matters: Strong subscription growth means more people are using new offerings.
Supportive ifSubscription revenue growth is over 30% year-over-year in the next quarter.
Worry ifSubscription revenue growth is below 30% compared to last year.
Why it matters: A stable net income margin shows better profits and efficiency.
Supportive ifNet income margin stabilizes above 4% in the next quarter.
Worry ifNet income margin falls below 4% in the next quarter.
Why it matters: A drop in cash flow from operations may show financial trouble and affect spending plans.
Worry ifCash flow from operations decreases below $70M in Q3.
Less concerning ifCash flow from operations stays above $80M in Q3.
Why it matters: If revenue growth is below this level, it shows trouble in keeping growth and margins.
Worry ifQ2 revenue growth reported below 5% year over year.
Less concerning ifQ2 revenue growth reported above 5% year over year.
Why it matters: Hitting this target shows the company is keeping costs low while making more money.
Supportive ifManagement says Adjusted EBITDA will be more than $235 million for FY 2026.
Worry ifAdjusted EBITDA falls below $225 million for FY 2026.